• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom claims win in patent war with AgaMatrix unit WaveForm

August 26, 2019 By Brad Perriello

Dexcom, AgaMatrixDexcom Inc. (NSDQ:DXCM) last week claimed a win along one front of its patent war with AgaMatrix subsidiary WaveForm Technologies, when an Oregon federal court dismissed a lawsuit alleging that its continuous glucose monitors infringe WaveForm patents.

Wilsonville, Ore.-based WaveForm sued Dexcom in March 2016, alleging infringement of a trio of patents covering a compound material analyte sensor and an indwelling analyte sensor by Dexcom’s G4 and G5 CGMs, according to documents filed in the U.S. District Court for Oregon. In January the companies agreed to drop the indwelling sensor patent from the suit, after the U.S. Patent Trial & Appeal Board found the claims at issue in the lawsuit to be unpatentable.

Dexcom moved for summary judgment on the remaining two patents, asking Judge Michael Mosman to invalidate them for indefiniteness. Mosman approved that motion August 23, dismissing the case with prejudice, according to the documents.

“We are extremely pleased by the court’s ruling that Dexcom’s innovative and important technology helping people with diabetes is not in violation of WaveForm’s patents and that the patents should never have been granted in the first place,” general counsel Patrick Murphy said in prepared remarks. “This case and outcome demonstrate Dexcom’s commitment to defend itself against meritless infringement allegations.”

San Diego-based Dexcom came out on the losing end of another case, after it sued Salem, N.H.-based AgaMatrix in August 2016 in the U.S. District Court for Central California. That suit alleged infringement of a patent covering “Systems and Methods for Improving Electrochemical Analyte Sensors,” according to court documents.

In February 2018 Judge James Otero entered a judgment on non-infringement, prompting Dexcom to appeal to the U.S. Court of Appeals for the Federal Circuit, which upheld the lower court in March, according to the documents.

Filed Under: Diabetes, Featured, Legal News Tagged With: agamatrix, DexCom Inc., waveformtechnologies

IN CASE YOU MISSED IT

  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS